{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:17:28Z","timestamp":1793675848542,"version":"4.5.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jtct.2024.01.073","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T21:10:39Z","timestamp":1706303439000},"page":"404-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1952","authenticated-orcid":false,"given":"Naokazu","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-0421","authenticated-orcid":false,"given":"Tomoyasu","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-3442","authenticated-orcid":false,"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-2162","authenticated-orcid":false,"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisaki","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-6145","authenticated-orcid":false,"given":"Miki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.01.073_bib0001","first-page":"633","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","author":"Gisselbrecht","year":"2018182","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.01.073_bib0002","first-page":"1800","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","author":"Crump","year":"2017130","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.01.073_bib0003","first-page":"439","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","author":"Maude","year":"2018378","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.01.073_bib0004","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.01.073_bib0005","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.01.073_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.jtct.2024.01.073_bib0007","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.01.073_bib0008","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2024.01.073_bib0009","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.01.073_bib0010","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.01.073_bib0011","doi-asserted-by":"crossref","first-page":"e889","DOI":"10.1097\/HS9.0000000000000889","article-title":"An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2024.01.073_bib0012","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.01.073_bib0013","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2024.01.073_bib0014","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2024.01.073_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.01.073_bib0016","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.jtct.2024.01.073_bib0017","unstructured":"Novartis Pharmaceuticals Corp. Important safety information. Kymriah (tisagenlecleucel). 2022. Available at: https:\/\/www.hcp.novartis.com\/products\/kymriah\/acute-lymphoblastic-leukemia-children\/safety-profile\/#cytokine-release-syndrome. Accessed November 27, 2023."},{"key":"10.1016\/j.jtct.2024.01.073_bib0018","unstructured":"Bristol Myers Squibb. Breyanzi (lisocabtagene maraleucel). 2022. Available at: https:\/\/www.breyanzi.com\/assets\/commercial\/us\/breyanzidtc\/en\/pdfs\/Breyanzi_Doctor_Discussion_Guide.pdf. Accessed November 27, 2023."},{"key":"10.1016\/j.jtct.2024.01.073_bib0019","unstructured":"Kite Pharma, Inc. Highlights of prescribing information. Yescarta (axicabtagene ciloleucel). 2023. Available at: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/yescarta\/yescarta-pi.pdf. Accessed November 27, 2023."},{"key":"10.1016\/j.jtct.2024.01.073_bib0020","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.18504","article-title":"Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy","volume":"200","author":"Nakamura","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.01.073_bib0021","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th Edition)","author":"Swerdlow","year":"2017","journal-title":"Lyon: International Agency for Research on Cancer (IARC)"},{"key":"10.1016\/j.jtct.2024.01.073_bib0022","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2024.01.073_bib0023","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.01.073_bib0024","first-page":"452","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","author":"Kanda Y","year":"201348","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.01.073_bib0027","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2024.01.073_bib0028","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.jtct.2024.01.073_bib0029","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/bjh.18790","article-title":"What drives CAR-T emergent cytopenia?","volume":"202","author":"Hills","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.01.073_bib0030","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.bulcan.2021.05.003","article-title":"CAR-T cell: Toxicities issues: mechanisms and clinical management","volume":"108","author":"Wallet","year":"2021","journal-title":"Bull Cancer"},{"key":"10.1016\/j.jtct.2024.01.073_bib0031","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.01.073_bib0032","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.01.073_bib0033","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41409-022-01771-x","article-title":"Management of prolonged cytopenia following CAR T-cell therapy","volume":"57","author":"Corona","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.01.073_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2024.01.073_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215920","article-title":"Hematologic cytopenia post-CAR T cell therapy: etiology, potential mechanisms and perspective","volume":"550","author":"Si","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jtct.2024.01.073_bib0034","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjh.18747","article-title":"Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy","volume":"202","author":"Kitamura","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.01.073_bib0035","doi-asserted-by":"crossref","unstructured":"Jo T, Arai Y, Kitawaki T, et al. KyoTox-e score; prediction of post-CAR-T prolonged thrombocytopenia using peripheral blood data before apheresis [e-pub ahead of print]. Bone Marrow Transplant. https:\/\/doi.org\/10.1038\/s41409-023-02175-1, Accessed December 19, 2023.","DOI":"10.1038\/s41409-023-02175-1"},{"key":"10.1016\/j.jtct.2024.01.073_bib0036","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12026-014-8590-4","article-title":"Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature","volume":"61","author":"Shovman","year":"2015","journal-title":"Immunol Res"},{"key":"10.1016\/j.jtct.2024.01.073_bib0037","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jbspin.2017.02.012","article-title":"Sustained tocilizumab-induced hypofibrinogenemia and thrombocytopenia. Comment on: \u201cTocilizumab-induced hypofibrinogenemia: A report of 7 cases\u201d by Martis et al","volume":"84","author":"Vitiello","year":"2017","journal-title":"Joint Bone Spine"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724001702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724001702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T01:59:23Z","timestamp":1729130363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724001702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2666636724001702"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.01.073","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.01.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}